#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need standardized guidance on medicinal cannabis dosing, strain selection, and safety to make informed prescribing decisions and reduce variability in patient outcomes. Clear regulatory pathways from professional medical bodies like CREMESP improve access for patients with conditions like chronic pain or chemotherapy-induced nausea while establishing accountability for adverse effects monitoring. This guidance helps clinicians integrate cannabis therapeutics into evidence-based practice rather than leaving patients to self-manage or seek unregulated alternatives.
CREMESP, the medical council regulating physicians in São Paulo State, Brazil, has released clinical guidance on medicinal cannabis use that addresses phytocannabinoid pharmacology and establishes clinical distinctions between botanical cannabis strains, including Cannabis sativa varieties. This guidance clarifies the medical and scientific rationale for cannabis prescribing in regulated healthcare settings, potentially legitimizing clinical cannabis practice among Brazilian physicians who may have previously avoided the topic due to regulatory uncertainty. The distinction between strains carries direct clinical implications, as different Cannabis sativa chemotypes produce varying cannabinoid profiles that influence therapeutic effects and adverse event profiles relevant to patient selection and dosing. By providing authoritative professional guidance, CREMESP helps standardize cannabis medicine practice across São Paulo’s medical community and may influence prescribing patterns and patient access to evidence-based cannabis therapeutics. Clinicians in Brazil and similar jurisdictions should consult their medical regulatory bodies for comparable guidance to ensure compliant, standardized prescribing practices. For physicians considering cannabis prescribing, this type of regulatory guidance provides the professional legitimacy and strain-specific clinical frameworks needed to counsel patients on appropriate product selection and expected therapeutic outcomes.
“Clinical guidance documents like CREMESP’s help us move beyond anecdote toward more standardized practice, though I’d note that strain-level distinctions in botanical cannabis remain largely phenotypic rather than based on robust pharmacokinetic data in humans. As we integrate cannabis into evidence-based medicine, we need professional consensus frameworks, but we must also be honest about where our evidence still falls short.”
💊 Professional medical guidance on cannabis use remains nascent in many regions, and CREMESP’s release of formal recommendations represents an important step toward standardizing practice among Brazilian physicians. However, clinicians should recognize that botanical cannabis contains hundreds of compounds in variable ratios across strains, making individualized efficacy predictions challenging and limiting direct comparison to isolated pharmaceutical cannabinoids like dronabinol or nabiximols. The distinction between sativa and indica strains, while culturally embedded, lacks robust pharmacological validation for predicting clinical outcomes, and strain composition varies widely based on cultivation, processing, and storage conditions. Emerging clinical evidence supports cannabinoid use for specific indications such as chemotherapy-induced nausea, chronic pain, and certain seizure disorders, but evidence gaps remain substantial for many patient populations and long-term safety profiles. Practitioners should use CREMESP guidance as a foundation for informed decision-making while documenting careful patient
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
